Nuvoton Announces Feature-Packed Microcontrollers for CAN FD/USB and Ethernet/Crypto

Powerful 200 MHz Arm Core, Complete On-Chip Solution, and Application-Specific Features

Hsinchu, Taiwan – 1st December, 2023 – Nuvoton is pleased to announce its new feature-rich microcontrollers, the M463 CAN FD/USB HS Series and the M467 Ethernet/Crypto Series, which are ideal core components for numerous devices and systems, including IoT gateways, industrial control, telecoms, data centers, smart grid control, white goods motor control, small TFT LCDs, and TinyML (Machine Learning) products. The M463 is also great for gaming applications. There is support for numerous popular real-time operating systems (RTOS) and GUI libraries, and sample code is available for several use cases.

While the M463 and M467 share many features, including an Arm Cortex-M4F, both chips have unique special features that make them particularly suitable for certain purposes. The M463 emphasizes CAN FD (Controller Area Network Flexible Data-Rate) applications for sensor and control data, while the M467 provides greater on-chip support for network communication and strong hardware cryptography requirements.

NuMicro M463: A Complete CAN Solution in a Chip

The NuMicro® M463 CAN FD/USB HS series of 32-bit microcontrollers is based around the Arm Cortex-M4F core, with a DSP instruction set and single-precision floating-point unit (FPU). It offers up to 256 KB of Flash memory and up to 128 KB of SRAM, including hardware parity check.

Support for multiple digital and analog peripherals is on-chip, including 2 CAN FD buses to cut BOM costs, USB High-Speed OTG, up to 24 channels of 16-bit PWM, UART, SPI/I2S, Quad-SPI, I²C, analog comparators, and up to 16 channels of 12-bit SAR ADC.

The M463 core runs at up to 200 MHz, with a versatile operating voltage from 1.7 V to 3.6 V and a wide operating temperature range from -40 °C to 125 °C. Active power consumption is 135 μA/MHz at 25°C/3.3V (with peripherals off). Multiple low-power modes and power-saving capabilities, including wake on various external inputs, are built-in.

NuMicro M467: Everything Needed for Security and Network Connectivity

The NuMicro® M467 Ethernet/Crypto series is a 32-bit microcontroller based on the Arm Cortex-M4F core, with a DSP instruction set, single-precision floating-point unit (FPU) and Ethernet 10/100 MAC support. It provides up to 1024 KB of flash memory with a dual bank structure and supports Firmware Over-The-Air (FOTA) updating and up to 512 KB SRAM with hardware parity check. This chip provides rich analog peripherals, including 4 analog comparators, 3 12-bit SAR ADCs (up to 28 channels), and 2 channels of 12-bit DAC.

The M467 Ethernet/Crypto series supports plenty of peripherals, including Ethernet 10/100 MAC, hardware crypto engine, hardware key store, true random number generator (TRNG), programmable audio PLL, 4 CAN FD buses, USB HS OTG, USB FS OTG, up to 24 channels of 16-bit PWM, 10 UARTs, 4 SPI/I2S interfaces, 2 Quad-SPIs, 5 I²C buses, and 4 Quadrature Encoder Interfaces (QEI).

The M467 series operates as fast as 200 MHz, with a wide operating voltage from 1.7 V to 3.6 V and an operating temperature range from -40 °C to 105 °C. In operation, the chip consumes only 175 μA/MHz at 25°C/3.3V, with peripherals off. Numerous low power modes and power-saving features are built-in, including wake on various external inputs, including EMAC (Ethernet Media Access Controller).

Powerful Security: Protecting Code and Data and Users

Essential integrated security features included in both microcontrollers include Execute-Only-Memory (XOM) capability to protect confidential code from being copied; hardware secure boot; hardware key store; hardware AES-256 cryptography acceleration; plus a Pseudo Random Number Generator (PRNG) and a True Random Number Generator (TRNG). The M467 series adds a much wider range of hardware cryptography acceleration: as well as AES-256, it provides ECC-571, SHA-512, HMAC-512, RSA-4096, and SM2 acceleration.

Flexible Packaging Possibilities to Suit Any Application

These Nuvoton microcontrollers are both available in a wide variety of LQFP and QFN package sizes, with the size depending mainly on the number of dedicated I/O pins (from 48 up to 128 pins for the M463 and from 64 up to 176 pins for the M467). There are also variants with an exposed thermal pad (EPAD) for particular cooling requirements. Therefore, users can choose the most suitable package variant for their design or even scale it up or down with a small effort. Besides the I/O pin count and dimensions, almost all other features remain identical for each packaging variant.

Strong Evaluation, Design, and Development Tools for Fast Product Turn Around

Nuvoton provides the NuMaker-M467HJ evaluation board for the M467, the NuMaker-M463KG evaluation board for the M463, and the Nuvoton Nu-Link debugger. Third-party IDE support for both products includes Keil MDK, IAR EWARM, and Eclipse IDE with GNU GCC compilers. These tools provide a simple, consistent development environment for both products, based on familiar industry-standard software, thus reducing development time.

These products support real-time operating systems (RTOS) such as Mbed OS, Amazon FreeRTOS, and Zephyr. Supported GUI libraries include emWin and LVGL.

Sample code includes TinyML applications, such as keyword spotting, license plate recognition, image classification, visual wake words (people sensing), and gesture sensing. Sample code for an e-bike dashboard HMI/GUI on emWin Appwizard and for uploading data to the internet/cloud via TLS is also available.

Find Out More

M463 Series

M467 Series

About Nuvoton Technology

Nuvoton Technology Corporation (Nuvoton) was founded to bring innovative semiconductor solutions to the market. Nuvoton was spun-off as a Winbond Electronics affiliate in July 2008 and went public in September 2010 on the Taiwan Stock Exchange (TWSE). Nuvoton focuses on the development of microcontroller, microprocessor, smart home, cloud security IC, battery monitoring IC, components, visual sensing and IoT with security. The company has a strong market share in Industrial, Automotive, Communication, Consumer and Computer markets. Nuvoton owns 6-inch wafer fabs equipped with diversified processing technologies to provide professional wafer foundry services. Nuvoton provides products with a high performance/cost ratio for its customers by leveraging flexible technology, advanced design capability, and integration of digital and analog technologies. Nuvoton values long term relationships with its partners and customers and is dedicated to continuous innovation of its products, processes, and services. Nuvoton has established subsidiaries in the USA, China, Israel, India, Singapore, Korea and Japan to strengthen regional customer support and global management.

For more information, please visit http://www.nuvoton.com.

Media Contact
Company Name: GlobalPR Agency
Contact Person: Kayla Lee
Email: Send Email
Phone: +886-2-2882-5577
City: Taipei City
Country: Taiwan
Website: https://www.globalpr.agency/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Nuvoton Announces Feature-Packed Microcontrollers for CAN FD/USB and Ethernet/Crypto

Metastatic Breast Cancer Pipeline Drugs Analysis Report (2023 Updates): FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | RemeGen, SynCore Biotech, Allarity Therapeutics, Jiangsu

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Metastatic Breast Cancer pipeline constitutes 100+ key companies continuously working towards developing 100+ Metastatic Breast Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Metastatic Breast Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

“Metastatic Breast Cancer Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Metastatic Breast Cancer Market.

 

Some of the key takeaways from the Metastatic Breast Cancer Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Metastatic Breast Cancer treatment therapies with a considerable amount of success over the years. 
  • Metastatic Breast Cancer companies working in the treatment market are RemeGen, SynCore Biotechnology, Byondis B.V., Sichuan Baili Pharmaceutical, Allarity Therapeutics, Jiangsu Hansoh Pharmaceutical, Kind Pharmaceuticals LLC, Shanghai Miracogen, Dantari, Inc., Phoenix Molecular Designs, Daiichi Sankyo, Rhizen Pharmaceuticals SA, Olema Oncology, Immutep S.A.S, Jiangsu HengRui Medicine, Genor Biopharma, and others, are developing therapies for the Metastatic Breast Cancer treatment 
  • Emerging Metastatic Breast Cancer therapies in the different phases of clinical trials are- Disitamab Vedotin, EndoTAG®-1 (SB05), trastuzumab duocarmazine, GNC 035, Stenoparib (2X-121), HS-10342, AND019, MRG002, DAN-222, PMD-026, Patritumab Deruxtecan, Tenalisib, OP-1250, Eftilagimod alpha, SHR-A1811, GB491+ Fulvestrant, and others are expected to have a significant impact on the Metastatic Breast Cancer market in the coming years.   
  • On May 04, 2022, Rhizen Pharmaceuticals AG revealed positive interim findings from an ongoing Phase 2 trial assessing Tenalisib in individuals with locally advanced or metastatic breast cancer during the ESMO Breast Cancer Meeting in Berlin, Germany from May 3-5, 2022. The data showcased that Tenalisib demonstrated favorable tolerability and promising initial effectiveness when used as a standalone treatment in both primary and secondary resistant metastatic breast cancer (mBC). These encouraging results provide substantial support for the continued advancement of Tenalisib as a prospective treatment option for patients diagnosed with HR+ and HER2- MBC.
  • In April 2022, Alphamab Oncology made an announcement regarding the presentation of data from the phase II clinical trial featuring the chemo-free treatment regimen involving KN026 alongside KN046 (KN026-203) at the AACR Annual Meeting 2022 (AACR 2022) via an E-poster. Up until August 10, 2021, a total of 24 patients diagnosed with HER2-positive solid tumors other than breast or gastric cancer, who had previously received at least one line of systemic therapy, were enrolled. Among these patients, 20 were eligible for overall response assessment. The results indicated an overall response rate (ORR) of 55.0%, a disease control rate (DCR) of 85.0%, and a 6-month progression-free survival (PFS) rate of 84.1%. Furthermore, among the 11 colorectal cancer (CRC) patients evaluated, the ORR stood at 45.5%, while the DCR was notably higher at 90.9%.
  • In April 2022, Quantum Leap Healthcare Collaborative™ (Quantum Leap) and Ambrx Biopharma Inc. disclosed their decision to include Ambrx’s antibody-drug conjugate (ADC) ARX788 as a fresh investigational treatment arm in the I-SPY 2.2 TRIAL intended for managing HER2-positive breast cancer in the neoadjuvant setting. Spearheaded by Quantum Leap, the I-SPY 2.2 TRIAL extends the objectives of the I-SPY 2 TRIAL by customizing treatments for individual patients to enhance clinical outcomes.
  • In March 2022, The Georgetown University researchers that submitted the poster abstract, “SM-88, D/L-alpha-metyrosine, is a novel anti-cancer agent in estrogen receptor-positive breast cancer,” have made it available, according to TYME Technologies, Inc. The abstract was given at the 2022 Annual Meeting of the American Association for Cancer Research (AACR) in New Orleans, Louisiana.  The Phase II OASIS trial, which is being conducted by Georgetown University (NCT04720664) at several MedStar Health hospitals, is for patients with metastatic hormone receptor-positive, human epidermal growth factor receptor 2 negative (“HR+/HER2-“) breast cancer who have previously received a CDK4/6 inhibitor regimen. TYME Technologies, Inc. announced in September 2021 that the first patient had been dosed in this trial. Georgetown’s academic clinical partner is MedStar Health.
  • In February 2022, In their Phase 1b monotherapy clinical trial, Phoenix Molecular Designs (PhoenixMD) has stated that patient recruitment and PMD-026 dosing are now complete. PhoenixMD has made significant progress toward moving PMD-026 into Phase 2 combo trials for triple-negative breast cancer (TNBC) and hormone-positive breast cancer with the successful completion of patient enrollment in this Phase 1/1b trial.
  • In December 2021, A new PROTAC® estrogen receptor (ER) degrader, ARV-471, is being co-developed by Arvinas, Inc. and Pfizer Inc. to treat patients with locally advanced or metastatic ER-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer (ER+/HER2-). The companies recently released Phase 1 dose-escalation data.
  • In August 2021, Disitamab vedotin is a new ADC that targets the HER2 receptor. Seagen Inc. and RemeGen Co., Ltd. announced that they have entered into an exclusive worldwide licensing deal to develop and market the drug.
  • In September 2021, A Phase III clinical trial of GB491 plus Fulvestrant was started by Genor Biopharma for patients with HR+, HER2-, locally advanced or metastatic breast cancer who had not responded to previous endocrine therapy. The trial was randomized, double-blind, placebo-controlled.

 

Metastatic Breast Cancer Overview

When breast cancer spreads to another area of the body, usually the brain, liver, lungs, or bones, it is referred to as metastatic breast cancer, also known as stage IV breast cancer. Many months or years after the initial diagnosis and treatment, breast cancer may recur in a different place of the body.

 

Get a Free Sample PDF Report to know more about Metastatic Breast Cancer Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/metastatic-breast-cancer-pipeline-insight

 

Emerging Metastatic Breast Cancer Drugs Under Different Phases of Clinical Development Include:

  • Disitamab Vedotin: RemeGen
  • EndoTAG®-1 (SB05): SynCore Biotechnology
  • trastuzumab duocarmazine: Byondis B.V.
  • GNC 035: Sichuan Baili Pharmaceutical Co., Ltd
  • Stenoparib (2X-121): Allarity Therapeutics
  • HS-10342: Jiangsu Hansoh Pharmaceutical Co., Ltd.
  • AND019: Kind Pharmaceuticals LLC
  • MRG002: Shanghai Miracogen Inc
  • DAN-222: Dantari, Inc.
  • PMD-026: Phoenix Molecular Designs
  • Patritumab Deruxtecan: Daiichi Sankyo Co., Ltd.
  • Tenalisib: Rhizen Pharmaceuticals SA
  • OP-1250: Olema Oncology
  • Eftilagimod alpha: Immutep S.A.S
  • SHR-A1811: Jiangsu HengRui Medicine Co., Ltd.
  • GB491+ Fulvestrant : Genor Biopharma Co., Ltd

 

Metastatic Breast Cancer Route of Administration

Metastatic Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type

 

Metastatic Breast Cancer Molecule Type

Metastatic Breast Cancer Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type 

 

Metastatic Breast Cancer Pipeline Therapeutics Assessment

  • Metastatic Breast Cancer Assessment by Product Type
  • Metastatic Breast Cancer By Stage and Product Type
  • Metastatic Breast Cancer Assessment by Route of Administration
  • Metastatic Breast Cancer By Stage and Route of Administration
  • Metastatic Breast Cancer Assessment by Molecule Type
  • Metastatic Breast Cancer by Stage and Molecule Type

 

DelveInsight’s Metastatic Breast Cancer Report covers around 100+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Metastatic Breast Cancer product details are provided in the report. Download the Metastatic Breast Cancer pipeline report to learn more about the emerging Metastatic Breast Cancer therapies

 

Some of the key companies in the Metastatic Breast Cancer Therapeutics Market include:

Key companies developing therapies for Metastatic Breast Cancer are – RemeGen, SynCore Biotechnology, Allarity Therapeutics, Daiichi Sankyo Company, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Byondis B.V., Jiangsu Hansoh Pharmaceutical Co., Ltd., Shanghai Miracogen Inc., Ambrx, Inc., Daehwa Pharmaceutical Co., Ltd., Phoenix Molecular Designs, Menarini Group, Samus Therapeutics, Inc., Hanmi Pharmaceutical Company Limited, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Immutep Limited, Arvinas Inc., G1 Therapeutics, Mirati Therapeutics Inc., Chia Tai Tianqing Pharmaceutical, Shanghai Pharmaceuticals Holding Co., Ltd, Pfizer, OncoTherapy Science, Inc., Eisai Inc., Dizal Pharmaceuticals, and others.

 

Metastatic Breast Cancer Pipeline Analysis:

The Metastatic Breast Cancer pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Metastatic Breast Cancer with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Breast Cancer Treatment.
  • Metastatic Breast Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Metastatic Breast Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Metastatic Breast Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Metastatic Breast Cancer drugs and therapies

 

Metastatic Breast Cancer Pipeline Market Drivers

  • Increasing prevalence of breast cancer, launch of several diagnostic and screening programs are some of the important factors that are fueling the Metastatic Breast Cancer Market.

 

Metastatic Breast Cancer Pipeline Market Barriers

  • However, high cost associated with the treatment, several side effects associated with the use of breast cancer therapeutics and other factors are creating obstacles in the Metastatic Breast Cancer Market growth.

 

Scope of Metastatic Breast Cancer Pipeline Drug Insight    

  • Coverage: Global
  • Key Metastatic Breast Cancer Companies: RemeGen, SynCore Biotechnology, Byondis B.V., Sichuan Baili Pharmaceutical, Allarity Therapeutics, Jiangsu Hansoh Pharmaceutical, Kind Pharmaceuticals LLC, Shanghai Miracogen, Dantari, Inc., Phoenix Molecular Designs, Daiichi Sankyo, Rhizen Pharmaceuticals SA, Olema Oncology, Immutep S.A.S, Jiangsu HengRui Medicine, Genor Biopharma, and others
  • Key Metastatic Breast Cancer Therapies: Disitamab Vedotin, EndoTAG®-1 (SB05), trastuzumab duocarmazine, GNC 035, Stenoparib (2X-121), HS-10342, AND019, MRG002, DAN-222, PMD-026, Patritumab Deruxtecan, Tenalisib, OP-1250, Eftilagimod alpha, SHR-A1811, GB491+ Fulvestrant, and others
  • Metastatic Breast Cancer Therapeutic Assessment: Metastatic Breast Cancer current marketed and Metastatic Breast Cancer emerging therapies
  • Metastatic Breast Cancer Market Dynamics: Metastatic Breast Cancer market drivers and Metastatic Breast Cancer market barriers 

 

Request for Sample PDF Report for Metastatic Breast Cancer Pipeline Assessment and clinical trials

 

Table of Contents

1. Metastatic Breast Cancer Report Introduction

2. Metastatic Breast Cancer Executive Summary

3. Metastatic Breast Cancer Overview

4. Metastatic Breast Cancer- Analytical Perspective In-depth Commercial Assessment

5. Metastatic Breast Cancer Pipeline Therapeutics

6. Metastatic Breast Cancer Late Stage Products (Phase II/III)

7. Metastatic Breast Cancer Mid Stage Products (Phase II)

8. Metastatic Breast Cancer Early Stage Products (Phase I)

9. Metastatic Breast Cancer Preclinical Stage Products

10. Metastatic Breast Cancer Therapeutics Assessment

11. Metastatic Breast Cancer Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Metastatic Breast Cancer Key Companies

14. Metastatic Breast Cancer Key Products

15. Metastatic Breast Cancer Unmet Needs

16 . Metastatic Breast Cancer Market Drivers and Barriers

17. Metastatic Breast Cancer Future Perspectives and Conclusion

18. Metastatic Breast Cancer Analyst Views

19. Appendix

20. About DelveInsight

 

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Metastatic Breast Cancer Pipeline Drugs Analysis Report (2023 Updates): FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | RemeGen, SynCore Biotech, Allarity Therapeutics, Jiangsu

Schneider Electric calls for greater action on decarbonisation and inclusion

Schneider Electric, a leader in the digital transformation of energy management and automation, has called for greater collective action to decarbonise the global economy and ensure a fair and inclusive transition to net-zero, and detailed the actions it is taking at the upcoming COP28 United Nations Climate Change Conference to support these efforts.

Thousands of government and private-sector leaders, climate experts, NGOs, youth groups and other stakeholders will gather for the event, which takes place in Dubai on 30 November – December 12, to foster collaboration, ideas and initiatives to tackle climate change and deliver on common sustainability ambitions. A key focus will be the publication of the first Global Stocktake, a comprehensive assessment of progress achieved since the 2015 Paris Climate Change Agreement.

With energy at the heart of over 70% of carbon emissions, Schneider Electric delegates will highlight the untapped potential of electrification, automation and digital technologies, and showcase the social and economic benefits of deploying such solutions in industries, buildings, homes, data centres, infrastructure, and transportation.

“We have plenty of technologies at our disposal today. It’s time to recognise that deploying these at much greater speed and scale brings social, environmental, economic and job-creation benefits, that they can lower emissions and costs faster than many realise – and that inaction is simply not an option,” said Peter Herweck, CEO of Schneider Electric.

The company will host discussions and showcase solutions in the COP28 Technology & Innovation Hub. Schneider Electric delegates will participate in a number of panel discussions to share news and insights on corporate decarbonisation, youth empowerment and supply chain engagement. In addition, Schneider will:

  • release fresh geographically relevant insights on ways to accelerate decarbonisation, building on its Back to 2050 research.
  • extend several Schneider Electric Foundation partnerships, in line with its longstanding mission to support the empowerment of younger generations and women through education and training in the energy sector.
  • announce new strategic partnerships and initiatives to extend the decarbonisation of its supply chain, and launch a report on supply chain decarbonisation developed in partnership with Women Action Sustainability (WAS).

“As the world’s population and economies continue to grow, we must develop energy efficiency as well as clean, affordable energy. New technologies of digitisation of everything leveraging IoT, big data and AI, as well as low-carbon electrification are the two major disruptors of our relationship to energy.

“Accelerated adoption of these technologies and new ways of designing are essential pillars of innovative, collective, fair and inclusive climate action,” said Jean-Pascal Tricoire, Chairman of Schneider Electric. “The corporate world, including impact companies like ours, needs to be a player and enabler of sustainability action worldwide, inspiring and supporting governments, societies, the academic and business world, and others, to accelerate action.”

About Schneider Electric

Schneider’s purpose is to empower all to make the most of our energy and resources, bridging progress and sustainability for all. We call this Life Is On.

Our mission is to be your digital partner for Sustainability and Efficiency.

We drive digital transformation by integrating world-leading process and energy technologies, end-point to cloud connecting products, controls, software and services, across the entire lifecycle, enabling integrated company management, for homes, buildings, data centers, infrastructure and industries.

Media Contact
Company Name: ABC Private Limited
Contact Person: Media Relations
Email: Send Email
Country: India
Website: https://www.se.com/in/en/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Schneider Electric calls for greater action on decarbonisation and inclusion

Jacqueline Rolston: “CHRISTMAS LIST” – The Christmas Song of the Year

“CHRISTMAS LIST (Golden Phonograph Records) A Christmas Song by Jacqueline Rolston.”
Jacqueline Rolston’s upcoming single “CHRISTMAS LIST” promises to be a heartwarming Christmas hit, filled with positivity and joy. With captivating melodies and heartfelt lyrics, it encapsulates the essence of the season, urging us to embrace the true gifts of Christmas. Available globally on Spotify and all streaming platforms from December 1st.

The festive spirit is poised to fill our hearts with joy and hope, and this year, there’s an extra reason to smile. Jacqueline Rolston, the immensely talented songwriter, is set to gift us with an extraordinary musical present with her new single “CHRISTMAS LIST” (Golden Phonograph Records), slated for release on December 1, 2023, across all major streaming platforms. This track promises to be a Christmas hit that will convey a message of positivity and optimism, bringing a breath of hope into the world.

The magic of Christmas is beautifully encapsulated in “CHRISTMAS LIST,” a song that captures the essence of the season with stirring lyrics and engaging melodies. Jacqueline Rolston has crafted a festive anthem that invites us to contemplate the fundamental values of Christmas—sharing, love, and gratitude. Her enveloping and warm voice, coupled with exceptional musical arrangement, transports us on a sonic journey that dispels worries and envelops us in a cocoon of happiness.

“CHRISTMAS LIST” is a song about wishes, but not just material ones. Jacqueline Rolston urges us to create a list of desires that go beyond gifts under the tree — a list that encompasses moments of joy with the people we cherish. It’s a reminder that life’s most precious gifts are often intangible, found in relationships and shared moments with others.

In a time when the world has faced significant challenges, this song is a ray of light that brings us back to the beauty of the Christmas season. “CHRISTMAS LIST” is an anthem of optimism and hope, a message that finds its way through the notes and verses of this wonderful song.

Jacqueline Rolston is not only an extraordinary songwriter but also a voice that conveys deep and authentic emotions. Her talent shines through every note, and “CHRISTMAS LIST” is yet another testament to her ability to create music that touches the heart.

Are you ready to immerse yourself in the magical atmosphere of Christmas? Mark your calendars: on December 1st, “CHRISTMAS LIST” will be available on all streaming platforms. This song is destined to become a Christmas classic, spreading joy and hope worldwide. Don’t miss the chance to listen to this extraordinary Christmas song and share its positive message with all those you love. Jacqueline Rolston has gifted us with a true musical gem, and it’s time to share it with the world. Merry Christmas!

Available on Spotify and all digital streaming service providers worldwide starting from December 1st. 

Media Contact
Company Name: MAGIC&UNIQUE GROUP
Contact Person: JP DEVERA
Email: Send Email
Phone: +1 424 777 2283
City: LOS ANGELES
Country: United States
Website: www.magicandunique.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Jacqueline Rolston: \”CHRISTMAS LIST\” – The Christmas Song of the Year

Rheumatoid Arthritis Pipeline Analysis, 2023 Updates | Latest FDA, EMA, and PMDA Approvals | Bristol-Myers Squibb Company, Celgene Corporation, F. Hoffmann-La, Roche AG, AbbVie Inc., Amgen Inc

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Rheumatoid Arthritis pipeline constitutes 7+ key companies continuously working towards developing 8+ Rheumatoid Arthritis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Rheumatoid Arthritis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

“Rheumatoid Arthritis Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Rheumatoid Arthritis Market.

 

Some of the key takeaways from the Rheumatoid Arthritis Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Rheumatoid Arthritis treatment therapies with a considerable amount of success over the years. 
  • Rheumatoid Arthritis companies working in the treatment market are Sonoma Biotherapeutics, OncoOne, Oryn Therapeutics, Biopharma Co. Ltd., Teijin Pharma, Revolo Biotherapeutics, Eli Lilly and Company, Philogen, SynAct Pharma, RemeGen, SinoMab Bioscience, and others, are developing therapies for the Rheumatoid Arthritis treatment 
  • Emerging Rheumatoid Arthritis therapies in the different phases of clinical trials are- SBT-77-7101, ON104, ORTD 1, TJ003234 I-Mab, TCK-276, IRL-201805, LY3462817, Dekavil, AP1189, RC18, SM03, and others are expected to have a significant impact on the Rheumatoid Arthritis market in the coming years.   
  • In February 2022, The FDA in the United States has agreed to review the Prior Approval Supplement (PAS) to the Biologics License Application (BLA) for ABRILADA (adalimumab-afzb), considering it as an interchangeable biosimilar to Humira (adalimumab).
  • In February 2022, Biogen Inc and Xbrane Biopharma AB have formed a commercialization and licensing agreement aimed at developing, manufacturing, and marketing Xcimzane. This preclinical monoclonal antibody serves as a potential biosimilar referencing CIMZIA (certolizumab pegol) for the treatment of rheumatoid arthritis.
  • In November 2021, SinoMab BioScience Limited disclosed the completion of the targeted enrollment of 510 patients in the Phase III clinical trial for rheumatoid arthritis (RA) involving SM03 (Suciraslimab). The study findings indicated that Suciraslimab administered at a dose of 600 mg with 4 and 6 infusions respectively demonstrated both effectiveness and favorable tolerance over the 24-week treatment period compared to the placebo group.

 

Rheumatoid Arthritis Overview

An autoimmune disease of the joints known as rheumatoid arthritis (RA) is characterized by extraarticular involvement in addition to inflammatory arthritis. Both hands are typically affected, and morning stiffness that might continue for several hours is usual.

 

Get a Free Sample PDF Report to know more about Rheumatoid Arthritis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/rheumatoid-arthritis-ra-pipeline-insight

 

Emerging Rheumatoid Arthritis Drugs Under Different Phases of Clinical Development Include:

  • SBT-77-7101: Sonoma Biotherapeutics
  • ON104: OncoOne
  • ORTD 1: Oryn Therapeutics
  • TJ003234 I-Mab: Biopharma Co. Ltd.
  • TCK-276: Teijin Pharma
  • IRL-201805: Revolo Biotherapeutics
  • LY3462817: Eli Lilly and Company
  • Dekavil: Philogen
  • AP1189: SynAct Pharma
  • RC18: RemeGen
  • SM03: SinoMab Bioscience

 

Rheumatoid Arthritis Route of Administration

Rheumatoid Arthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical

 

Rheumatoid Arthritis Molecule Type

Rheumatoid Arthritis Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy 

 

Rheumatoid Arthritis Pipeline Therapeutics Assessment

  • Rheumatoid Arthritis Assessment by Product Type
  • Rheumatoid Arthritis By Stage and Product Type
  • Rheumatoid Arthritis Assessment by Route of Administration
  • Rheumatoid Arthritis By Stage and Route of Administration
  • Rheumatoid Arthritis Assessment by Molecule Type
  • Rheumatoid Arthritis by Stage and Molecule Type

 

DelveInsight’s Rheumatoid Arthritis Report covers around 5+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Rheumatoid Arthritis product details are provided in the report. Download the Rheumatoid Arthritis pipeline report to learn more about the emerging Rheumatoid Arthritis therapies

 

Some of the key companies in the Rheumatoid Arthritis Therapeutics Market include:

Key companies developing therapies for Rheumatoid Arthritis are – Bristol-Myers Squibb Company, Celgene Corporation, F. Hoffmann-La, Roche AG, AbbVie Inc., Amgen Inc. Bayer AG, Boehringer Ingelheim GmbH, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Lupin Limited, Alkem Laboratories, Regeneron Pharmaceuticals, Eli Lilly and Company, Pfizer Inc, and others.

 

Rheumatoid Arthritis Pipeline Analysis:

The Rheumatoid Arthritis pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Rheumatoid Arthritis with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Rheumatoid Arthritis Treatment.
  • Rheumatoid Arthritis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Rheumatoid Arthritis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Rheumatoid Arthritis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Rheumatoid Arthritis drugs and therapies

 

Rheumatoid Arthritis Pipeline Market Drivers

  • Rising prevalence of arthritis and other joint disorders, rising combinational therapy of biologics for the treatment of Rheumatoid Arthritis, rich emerging pipeline, acceptance of biosimilars for treatment of Rheumatoid Arthritis are some of the important factors that are fueling the Rheumatoid Arthritis Market.

 

Rheumatoid Arthritis Pipeline Market Barriers

  • However, high cost of biologics, low adherence to the drugs, lack of daily assessment, Rheumatoid Arthritis delay in RA diagnosis and other factors are creating obstacles in the Rheumatoid Arthritis Market growth.

 

Scope of Rheumatoid Arthritis Pipeline Drug Insight    

  • Coverage: Global
  • Key Rheumatoid Arthritis Companies: Sonoma Biotherapeutics, OncoOne, Oryn Therapeutics, Biopharma Co. Ltd., Teijin Pharma, Revolo Biotherapeutics, Eli Lilly and Company, Philogen, SynAct Pharma, RemeGen, SinoMab Bioscience, and others
  • Key Rheumatoid Arthritis Therapies: SBT-77-7101, ON104, ORTD 1, TJ003234 I-Mab, TCK-276, IRL-201805, LY3462817, Dekavil, AP1189, RC18, SM03, and others
  • Rheumatoid Arthritis Therapeutic Assessment: Rheumatoid Arthritis current marketed and Rheumatoid Arthritis emerging therapies
  • Rheumatoid Arthritis Market Dynamics: Rheumatoid Arthritis market drivers and Rheumatoid Arthritis market barriers 

 

Request for Sample PDF Report for Rheumatoid Arthritis Pipeline Assessment and clinical trials

 

Table of Contents

1. Rheumatoid Arthritis Report Introduction

2. Rheumatoid Arthritis Executive Summary

3. Rheumatoid Arthritis Overview

4. Rheumatoid Arthritis- Analytical Perspective In-depth Commercial Assessment

5. Rheumatoid Arthritis Pipeline Therapeutics

6. Rheumatoid Arthritis Late Stage Products (Phase II/III)

7. Rheumatoid Arthritis Mid Stage Products (Phase II)

8. Rheumatoid Arthritis Early Stage Products (Phase I)

9. Rheumatoid Arthritis Preclinical Stage Products

10. Rheumatoid Arthritis Therapeutics Assessment

11. Rheumatoid Arthritis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Rheumatoid Arthritis Key Companies

14. Rheumatoid Arthritis Key Products

15. Rheumatoid Arthritis Unmet Needs

16 . Rheumatoid Arthritis Market Drivers and Barriers

17. Rheumatoid Arthritis Future Perspectives and Conclusion

18. Rheumatoid Arthritis Analyst Views

19. Appendix

20. About DelveInsight

 

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Rheumatoid Arthritis Pipeline Analysis, 2023 Updates | Latest FDA, EMA, and PMDA Approvals | Bristol-Myers Squibb Company, Celgene Corporation, F. Hoffmann-La, Roche AG, AbbVie Inc., Amgen Inc

New Powerful and Exciting TV Shows, Masterclasses, Movies, and Winners on JD3TV

Chicago, IL, USA – December 1, 2023 – JD3TV, the premier streaming platform that prioritizes its viewers’ experience, is thrilled to unveil an exciting array of new programming and opportunities tailored to its valued members. This expansion reflects JD3TV’s unwavering commitment to delivering exceptional content and fostering a thriving community of engaged viewers.

“Survivor’s Jewelz”

Experience the transformational power of “Survivor’s Jewelz” with Kendra Hall and the legendary mogul Master P! In an exclusive clip, he reveals how putting God first, investing in yourself, and assembling an unbeatable team transformed his life. Don’t miss this electrifying moment on Survivor’s Jewelz! Tap into a legend’s wisdom and ignite your journey to success.

“Confidently Courageous”

“Confidently Courageous” is now streaming on JD3TV, bringing a treasure trove of insights on health, wellness, lifestyle, accessibility, and inclusivity. This is just the beginning, as in the weeks to come, Jasmin Murphy, who has lost over 414 pounds, has changed her life and will be bringing you powerful, life-changing, exclusive content.

Imagine a space where meal plans, exercise routines, and daily activities are reimagined to instill hope in plus-size women, along with personal and spiritual development sessions to ignite the leader within, fostering communities that embrace inclusion, celebrate diversity and achieve equality.

“The Power of 52 Podcast”

Welcome to “The Power of 52 Podcast.” A unique project that shines the spotlight on 52 women in business, projects, and movements from across the globe. By celebrating their journeys, sharing their legacy, and inspiring future generations, this podcast seeks to empower women everywhere. Whether you’re a woman in business or simply looking for inspiration, The Power of 52 will surely move you. Join us as we awaken to the power of collaboration and celebrate the accomplishments of women around the world!

JD3TV is a groundbreaking platform that goes beyond traditional streaming services. It offers a unique social media channel where viewers can interact with celebrity hosts and fellow members, creating a vibrant and engaging community. The network’s “Live Stream capabilities” enhance the interactive experience, allowing real-time engagement with hosts and other viewers.

In addition to its social media and live streaming features, JD3TV provides a dedicated marketplace and events page. This platform empowers content creators to promote their merchandise, invite their audience to live events and connect with their community on a deeper level.

“We are adding 20 new shows, masterclasses, movies, and a monthly live mastermind session every month to help our members grow personally and professionally,” says founder Sir Dr. James Dentley. “These new additions will cover various topics, including personal growth, professional development, health, wellness, and lifestyle.”

JD3TV is also launching monthly live mastermind sessions, providing members with a unique opportunity to connect with other like-minded individuals and receive personalized guidance from experts. These sessions will cover various topics, helping members achieve their personal and professional goals.

Sir Dentley added, “We believe your success can be another person’s miracle! Together, we can create a bigger difference in our communities through our opportunity and social impact initiatives.”

JD3TV is committed to empowering content creators by providing them with a platform to showcase their work, collect their own data, sell their products and services, and earn residual income. This unique opportunity allows creators to build their following and achieve financial success.

JD3TV is also dedicated to positively impacting the world through its social impact initiatives. The platform recently awarded 75 complimentary luxury cruises to subscribers for referring new members. Additionally, every member has a personal referral link and can earn trips, prizes, and cash simply by referring others to join the community.

With its new programming, live mastermind sessions, and commitment to empowering content creators and making a positive impact, JD3TV is the premier streaming platform for those who want to grow personally and professionally while making a difference in the world.

Join the JD3TV Family

Watch exclusive originals and shows from your favorite channels, all in one place, using our app on Google Play and The App Store.

Join the JD3TV community today and experience the transformational power of entertainment with a purpose!

Available on Apple and Android phones and Roku. Coming in January to Amazon and Android TV.

About JD3 Media, Inc.:

JD3 Media, Inc. is the creator and owner of JD3TV, the streaming home where our viewers are the priority. Learn more at https://www.jd3tv.com and watch exclusive originals and shows from your favorite channels, all in one place, using our app on Google Play and The App Store.

Media Contact
Company Name: Vedette Global Media
Contact Person: Angel Tuccy
Email: Send Email
Phone: 720-257-9263
Country: United States
Website: https://vedetteglobalmedia.com

James McDowell’s Heartfelt Composition ‘My Godchild’ Offers Spiritual Guidance and Hope

James McDowell’s Heartfelt Composition ‘My Godchild’ Offers Spiritual Guidance and Hope

James McDowell, a composer from Maryland, shares a touching tribute through his latest composition, “My Godchild.” Crafted with heartfelt lyrics and sung in collaboration with Shannon Ramsey, this song holds a deep significance as it speaks to the special bond between a Godfather and his Godchild, aiming to offer guidance and support throughout her journey.

Available across multiple platforms such as YouTube, Apple Music, Spotify, and more, “My Godchild” by James McDowell featuring Shannon Ramsey is a testament to the cherished relationship between mentor and child. To purchase the MP3 version of the song, search “My Godchild, James McDowell” on Amazon.

Listen to “My Godchild” on Spotify: https://open.spotify.com/album/6RHKYK2bT6z5QBgEQAZSfY

Enjoy it on Apple Music: https://music.apple.com/us/album/my-godchild-feat-shannon-ramsey-single/1023605683

For an array of James McDowell’s compositions, explore: https://jamestunes.com/listening-station/ for many other songs

Watch the video on YouTube: https://www.youtube.com/watch?v=y-mg4o3jyGA

ABOUT

James is a composer from Maryland who began his career writing gospel songs in 1982. He continues to write a variety of songs including wedding music.

In 2002 James lost his vision because of a genetic problem. Due to that, as well as losses in his family, James’ music has begun to transition to different themes.

He says: “People are just trying to find something in life to give them comfort, joy, happiness, and HOPE. We need more positive messages in this world today! I want my music to promote a change for the better!

LINKS

YouTube: https://www.youtube.com/watch?v=y-mg4o3jyGA

Spotify: https://open.spotify.com/track/0dizkuBy82UMR0r23VRssg

SoundCloud: https://soundcloud.com/james-mcdowell-music

Media Contact
Company Name: James McDowell
Contact Person: Mario Palumbo (promoter)
Email: Send Email
Phone: 800-983-1362
City: Baltimore
State: MD
Country: United States
Website: https://www.youtube.com/watch?v=y-mg4o3jyGA

Unleashing the Sheer Brilliance of Electronic Dance and Deep House Music – Producer-DJ Mister Monj Channels Ecstasy

Unleashing the Sheer Brilliance of Electronic Dance and Deep House Music - Producer-DJ Mister Monj Channels Ecstasy
With a series of hit House blends, Mister Monj’s eclectic discography embodies his formidable decade-long journey in Deep House

With over 14,000+ streams on Spotify alone, Mister Monj’s discography has been experienced, loved, and ‘lived’ by hundreds of thousands of fans. His pulsating and enlivening tracks, “Still Miss You,” and “Somebody Get Down” present audiences the raw experience of euphoria and stand as proof of years of experience in the genre.

Over the past ten years, the artist has consistently released music that captivates listeners and finds its way to the summits of dance charts, radio airwaves, and digital platforms. His distinctive ability to intricately direct his music, combining well-selected rhythms with soul-penetrating vocals, has entrenched his place in the hearts of fans globally.

The trajectory of Mister Monj’s career is marked not only by his DJ prowess but also by his creative autonomy. His monthly releases bear witness to a practitioner deeply attuned to the nuances of House music, consistently delivering tracks that resonate with audiences on a profound level.

Each release becomes a leader in its own right, ascending dance charts and finding a home in the playlists of devoted listeners. In 2023, Mister Monj stands not just as an artist but as the visionary founder of Fashion House Mafia, a record label that, in less than a year, has made significant waves with its hit releases.

As a music producer who cherishes both tradition and innovation, Mister Monj remains at the forefront of the House music scene, continually pushing boundaries and introducing fresh sounds to his audience. Away from the pulsating beats and studio sessions, Mister Monj invites readers and potential collaborators to delve into his world.

For Mister Monj, music is not merely a career; it is a professional hobby that he wholeheartedly shares with the world. His releases, marked by deep fashion and rhythmic innovation, promise to keep enthusiasts grooving as he continues to shape the future of House and Deep House music.

Stream Mister Monj’s new music on his official music streaming platforms and follow the artist’s musical journey on Facebook and Instagram! The artist always remains open to collaborations and inquiries.

ABOUT

Mister Monj stands as a luminary, a sound producer and DJ whose journey commenced in the pulsating beats of 2006. Hailing from Antalya, Alanya, Türkiye, Mister Monj’s passion for music ignited at a tender age of four, as he grooved to the disco hits of the ’80s, foretelling the remarkable odyssey that awaited him.

His professional ascent unfolded gradually, marked by a pivotal moment in the second half of 2006 when Mister Monj graced his first DJ stage in a bustling capital’s bar.

From this point, the resonance of his beats echoed beyond the confines of local bars to the expansive waves of dance radio stations, earning him a coveted residency that endured for five prolific years. This early success became a foundation, propelling Mister Monj into the world of music creation, where he began crafting his unique House and Deep House sounds.

Links

Facebook: https://www.facebook.com/mistermonj

Instagram: https://www.instagram.com/djmonj/

YouTube: https://www.youtube.com/@MisterMonj

Spotify: https://open.spotify .com/artist/5Si1zaJQAMi6NB9AXDICC6

SoundCloud: https://soundcloud.com/mr-djmonj

LastFM: https://www.last.fm/ru/music/Mister+Monj

LinkedIn: https://linktr.ee/mistermonj

Media Contact
Company Name: Mister Monge
Contact Person: Michael
Email: Send Email
Phone: 800-983-1362
City: Antalya
State: Alanya
Country: Turkey
Website: https://www.facebook.com/mistermonj

Schneider Electric Announces $1,000,000 Pledge to the ‘Next Level Now’ Campaign to Support the Digital Transformation of the Channel

Schneider Electric is the first manufacturer to join the NAED Education & Research Foundation (NERF) program improving the impact and sustainability of the channel

Schneider Electric, the leader in the digital transformation of energy management and automation, today announced a $1,000,000 pledge to the NAED Education & Research Foundation (NERF) to support their Next Level Now campaign. Schneider Electric is the first manufacturer to join the industry-wide effort to develop insights, tools, and services that support the digital transformation and modernization of the distribution channel. 

Schneider Electric is a long-time member of NAED and the program’s first at the Visionary Circle level pledging $1,000,000 over the next five years. This investment will improve the impact and sustainability of the channel, as well as its modernization by developing strategies and tools to optimize business practices. Schneider Electric shares the vision of a modern, digital channel to benefit all stakeholders involved by engaging a new and larger customer base, increasing sales, and providing a better overall customer experience.

“We provide a shared experience to our customers, and the industry wins on the quality of that shared experience,” Mike Montanari, Vice-President of Channel Development, said. “The Next Level Now Campaign is an opportunity for us to align together so we can continually deliver the best possible experience for the customers we collectively serve. Schneider Electric is honored to support this vital initiative.”

With its five-year commitment to the program, Schneider Electric demonstrates the strength of its relationships with distribution partners and its leadership position in the industry as distributors explore and develop new capabilities to optimize their businesses and keep pace with customer expectations and needs.

About Schneider Electric

Schneider’s purpose is to empower all to make the most of our energy and resources, bridging progress and sustainability for all. We call this Life Is On.

Our mission is to be your digital partner for Sustainability and Efficiency.

We drive digital transformation by integrating world-leading process and energy technologies, end-point to cloud connecting products, controls, software and services, across the entire lifecycle, enabling integrated company management, for homes, buildings, data centers, infrastructure and industries.

We are the most local of global companies. We are advocates of open standards and partnership ecosystems that are passionate about our shared Meaningful Purpose, Inclusive and Empowered values.

Media Contact
Company Name: ABC Private Limited
Contact Person: Media Relations
Email: Send Email
Country: India
Website: https://www.se.com/in/en/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Schneider Electric Announces $1,000,000 Pledge to the \’Next Level Now\’ Campaign to Support the Digital Transformation of the Channel

Schneider Electric pledges $1 million to the “Next Level Now” campaign

Schneider Electric announced a $1,000,000 pledge to the NAED Education & Research Foundation (NERF) to support their Next Level Now campaign. Schneider Electric is the first manufacturer to join the industry-wide effort to develop insights, tools, and services that support the digital transformation and modernization of the distribution channel.

Schneider Electric is a long-time member of NAED and the program’s first at the Visionary Circle level pledging $1,000,000 over the next five years. This investment will improve the impact and sustainability of the channel, as well as its modernization by developing strategies and tools to optimize business practices. Schneider Electric shares the vision of a modern, digital channel to benefit all stakeholders involved by engaging a new and larger customer base, increasing sales, and providing a better overall customer experience.

“We provide a shared experience to our customers, and the industry wins on the quality of that shared experience,” said Mike Montanari, VP of channel development. “The Next Level Now Campaign is an opportunity for us to align together so we can continually deliver the best possible experience for the customers we collectively serve. Schneider Electric is honored to support this vital initiative.”

With its five-year commitment to the program, Schneider Electric demonstrates the strength of its relationships with distribution partners and its leadership position in the industry as distributors explore and develop new capabilities to optimize their businesses and keep pace with customer expectations and needs.

Schneider Electric
se.com

About Schneider Electric

Schneider’s purpose is to empower all to make the most of our energy and resources, bridging progress and sustainability for all. We call this Life Is On.

Our mission is to be your digital partner for Sustainability and Efficiency.

We drive digital transformation by integrating world-leading process and energy technologies, end-point to cloud connecting products, controls, software and services, across the entire lifecycle, enabling integrated company management, for homes, buildings, data centers, infrastructure and industries.

Media Contact
Company Name: ABC Private Limited
Contact Person: Media Relations
Email: Send Email
Country: India
Website: https://www.se.com/in/en/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Schneider Electric pledges $1 million to the \”Next Level Now\” campaign